Compugen Ltd (CGEN) stock

CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026Score 12/30

$2.10−0.02 (-0.94%)

Close on Nov 13, 2026Market cap $198.56MP/E 5.5Yield –

Compugen EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Compugen's EV/EBITDA was 4.7× on Nov 11, 2026.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	4.7×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CGEN.

Revenue growth161.1% · median -54.0%

Gross margin87.3% · median 39.5%

Operating margin43.1% · median -252.3%

Net margin48.6% · median -260.8%

Advertisement
300 × 250

See a number that looks wrong?